A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03951753 · Completed

Last updated 2026-05-28

This study is testing the medication tirzepatide in adults with type 2 diabetes to see how it affects their body's ability to control blood sugar levels.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 117 people

Who can join Ages 20–74 · all sexes

Timeline Started 2019-06 · est. completion 2021-04

Where 2 sites · Germany

What this study is testing ClinicalTrials.gov NCT03951753 ↗

Description as written by the study sponsor.

This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Semaglutide Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline in Total Clamp Disposition Index (cDI)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03951753 ↗